Here's Why BioMarin Pharmaceutical Leapt 10.2% in November
Shares of BioMarin Pharmaceutical (NASDAQ: BMRN) rose more than 10% last month, according to data from S&P Global Market Intelligence. The rare-disease specialist reported promising results from an ongoing phase 2 trial of an important drug candidate, held its annual research and development (R&D) day for investors, and submitted a marketing application for a gene therapy in the European Union.
Despite the monthly gains, shares of BioMarin Pharmaceutical have lost nearly 6% of their value since the beginning of 2019. It was much worse -- the pharma stock was down 24% on the same basis at the end of September -- but shares have rallied in recent months. Can it finish the year strong?
Image source: Getty Images.
Source Fool.com
